Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Sunshine Guojian Pharmaceutical (Shanghai) Co 14-Day RSI Related Terms
SHSE:688336 vs VRTX, REGN, RVMD: 14-Day RSI Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co 14-Day RSI vs Biotechnology Industry
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a 14-Day RSI of 43.31 as of Aug. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #375 out of 1420 companies in the Biotechnology industry, placing it in the top 26.4%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's 14-Day RSI too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current 14-Day RSI is 43.31. The Biotechnology industry median 14-Day RSI is 49.98. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 43.31 is 13.3% below this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #375 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #375 out of 1420 companies for 14-Day RSI. This puts Sunshine Guojian Pharmaceutical (Shanghai) Co in the upper half of its industry. The industry median 14-Day RSI is 49.98. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 43.31 is 13.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.98, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current 14-Day RSI of 43.31 is 13.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current 14-Day RSI is 43.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Possible Value Trap. The stock's GF Value™ is ¥66.10, compared to a current price of ¥43.46 — trading 34.3% below its estimated fair value. The current 14-Day RSI is 43.31 and 13.3% below the Biotechnology industry median of 49.98. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current 14-Day RSI is 43.31 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥43.46 is trading 34.3% below its estimated GF Value™ of ¥66.10.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Possible Value Trap.
Key valuation signals for SHSE:688336:
14-Day RSI: 43.31
GF Value™: ¥66.10 vs. price of ¥43.46 (34.3% below fair value)
Industry Position: 13.3% below the Biotechnology median (#375 of 1420)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
82GF Score
Get the complete analysis for SHSE:688336
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
